1. Home
  2. WYY vs TTRX Comparison

WYY vs TTRX Comparison

Compare WYY & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WidePoint Corporation

WYY

WidePoint Corporation

HOLD

Current Price

$10.75

Market Cap

107.8M

Sector

Technology

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$5.18

Market Cap

107.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WYY
TTRX
Founded
1991
2015
Country
United States
United States
Employees
N/A
2
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.8M
107.2M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
WYY
TTRX
Price
$10.75
$5.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$8.67
$8.00
AVG Volume (30 Days)
144.6K
57.9K
Earning Date
05-14-2026
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$150,545,364.00
N/A
Revenue This Year
$14.41
N/A
Revenue Next Year
$11.41
N/A
P/E Ratio
$1,127.00
N/A
Revenue Growth
5.59
N/A
52 Week Low
$2.80
$2.57
52 Week High
$12.25
$6.75

Technical Indicators

Market Signals
Indicator
WYY
TTRX
Relative Strength Index (RSI) 61.27 55.42
Support Level $4.76 $3.92
Resistance Level N/A $5.55
Average True Range (ATR) 1.20 0.59
MACD -0.04 0.03
Stochastic Oscillator 59.88 41.24

Price Performance

Historical Comparison
WYY
TTRX

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: